Research and development - Today Stories

Partnership Expands Reach of C2N’s Precivity™ Blood Tests in Over 75 Countries to Transform Alzheimer’s Disease Early Diagnosis and Research Agreement Plans to Facilitate a Technology Transfer of C2N’s Proprietary Portfolio of Alzheimer’s Blood Biomarkers to Deliver a Unilabs Testing Network Across Europe LOUIS, MO. and GENEVA, SWITZERLAND — August 7, 2024   Unilabs (“Unilabs”), a leading international provider of diagnostic services, and C2N Diagnostics, LLC (“C2N”),  a pioneer in advanced diagnostic solutions in the field of Alzheimer’s disease (AD) and related neurological disorders, today announced a major milestone in brain health diagnostics and research across Europe and beyond. Unilabs and C2N have signed a multi-year partnership agreement that will increase access to C2N’s Pr…

EQS-News: QUANTRO Therapeutics GmbH / Key word(s): MiscellaneousQUANTRO Therapeutics secures important Austrian research grant to accelerate development of cutting-edge platform06.08.2024 / 10:00 CET/CESTThe issuer is solely responsible for the content of this announcement. QUANTRO Therapeutics secures important Austrian research grant to accelerate development of cutting-edge platform Austrian Research Promotion Agency FFG awards funding to QUANTRO, accelerating the next development phase of its transcriptomic discovery platform Vienna (Austria), 06 August 2024: QUANTRO Therapeutics GmbH, a pioneer in the discovery of first-in-class transcription factor targeting cancer treatments, announced today that the company received an 18-month research grant awarded by the Austrian Research Promot…

New facility in San Diego will support continued development of Vividion’s global discovery and clinical portfolio and pave the way for future programs aimed at bringing first-in-class therapeutics to patients in need / Chemoproteomics screening capacity will increase by 50 percent to enable Vividion to pursue an expansive range of previously undrugged disease targets San Diego, USA, July 23, 2024 – Vividion Therapeutics, Inc. (Vividion), a clinical stage biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, today announced it will expand its global innovation capabilities with a new research and development (R&D) center and corporate headquart…

– RADIAN’s Five-Year, $25 Million Extension Will Increase Support for Local Organizations and Drive Progress to Help Turn the Tide on HIV Across the Region – – RADIAN Will Expand Geographic Focus to Provide Key Populations and Communities Impacted by the Conflict in Ukraine with HIV Prevention and Care Services – FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and the Elton John AIDS Foundation (EJAF) today announced a five-year extension of the RADIAN ® partnership to help meet the needs of the most vulnerable key populations in Eastern Europe and Central Asia (EECA) where the HIV epidemic is growing. RADIAN will continue supporting the initiatives of trusted, grassroots organizations who are working to address HIV-related challenges in the region. Anne Asle…

Cambridge, UK—10 July 2024: Cambridge Cognition, a leading provider of digital health solutions for brain health assessments has been included in the Bio-Hermes 2 project for its voice and touch-screen cognitive assessments, funded by the UK’s innovation agency, Innovate UK.  The Bio-Hermes 2 trial, led by the Global Alzheimer’s Platform Foundation (GAP), aims to determine how accurately digital and blood-based biomarkers, individually and in combination, can predict Alzheimer’s disease diagnosed definitively with positron emission tomography (PET) brain scans and clinical assessments. The upcoming trial will involve 1,000 participants over 24 months. Cambridge Cognition will collect speech biomarkers through its voice picture description tasks and conduct three touchscreen tasks tha…

Multi-year collaboration will initially focus on early discovery research for metabolic and infectious diseases Hamburg, Germany, 10 July 2024:Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced it has entered into a multi-year master research collaboration and option and license agreement with Pfizer. Under the agreement, Evotec and Pfizer will initially focus on early discovery research for metabolic and infectious diseases. The research will be carried out at Evotec’s sites in France, including Campus Curie in Toulouse, a state-of-the-art research site with capabilities spanning high throughput screening, in vitro and in vivo biology, proteomics and metabolomics. Evotec will receive research support funding from Pfizer and be eligibl…

The new research team at the BioMed X Institute in Heidelberg will develop a novel strategy to selectively target autoreactive plasma cells in autoimmune disease. HEIDELBERG/PARIS, June 3rd 2024 – BioMed X, an independent German biomedical research institute, and Servier, an international independent pharmaceutical company, announce the start of a new research team at the BioMed X Institute in Heidelberg to develop innovative strategies for neutralizing autoreactive plasma cells in the context of autoimmune diseases. Current therapeutic strategies for autoimmune diseases primarily focus on broadly suppressing the immune response, with significant side effects. More importantly, none of these treatments address one of the root causes of the disease, the autoreactive plasma cells that prod…

Connecticut Governor Ned Lamont, New Haven Mayor Justin Elicker, and Josh Geballe, Managing Director of Yale Ventures, participated in the launch ceremony of the new BioMed X Institute on Tuesday, June 11, 2024. New Haven, CT, USA, June 13, 2024 – BioMed X, an independent research institute founded in Heidelberg, Germany, has expanded its operations with the opening of a new institute in the United States. Located in New Haven, CT, in the vicinity of Yale University, the new facilities are part of the Elm City Bioscience Center, a state-of-the-art lab and research building owned by The Hurley Group. This significant milestone was celebrated with a grand opening ceremony on Tuesday, June 11, and attended by BioMed X fellows, partners, collaborators, and distinguished guests. Governor Ned…

New space recognises the need for more cost-effective bench space and flexible agreements for startups and spinouts  Sandwich, Kent, UK / 10th June 2024 / Discovery Park, Kent’s thriving life science community, has opened the doors to CoLab, a new shared lab facility. In partnership with Canterbury Christ Church University, CoLab has been specially designed for early-stage life science businesses, providing flexible bench space in a collaborative coworking environment. Dr Cornelia Wilson, Senior Lecturer and Academic Laboratory Director at Canterbury Christ Church University, said: “Finding lab space is too often a blocker for promising life science spin outs and startups, and CoLab exists to solve this. This specialist lab offers flexible and cost-effective space in a collaborative enviro…

Partnership will expand Evotec’s molecular patient database in the area of metabolic diseases and in particular obesity Evotec will leverage its leading PanOmics technologies for the generation of large omics data sets including transcriptomics, proteomics and metabolomics Lille University Hospital will provide human biological samples and associated clinical data from its ABOS Biobank and will collect specific human biosamples for the collaboration All parties will jointly identify and validate novel key mechanisms of obesity & other metabolic diseases based on human data sets Hamburg, Germany, 30 May 2024:Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that the Company entered a partnership with Inserm, the French National Ins…

The research of BioMed X team EPD – Early Intervention in Psychiatric Diseases – has shed light on the molecular mechanisms underlying white matter deficits in schizophrenia. HEIDELBERG, Germany, May 28, 2024 – German independent research institute BioMed X announces the successful completion of its second neuroscience project in partnership with Boehringer Ingelheim in the field of psychiatric disorders. The data resulting from this project have been acquired by Boehringer Ingelheim, where this research will be continued, potentially paving the way for novel therapies. This research project was launched in 2020 at the BioMed X Institute in Heidelberg and led by Dr. Ebru Ercan Herbst, now a professor at Reutlingen University, Germany. Her team has created both in vivo and in vitro platfo…

A new research team at XSeed Labs – a collaboration between BioMed X and Boehringer Ingelheim, will develop disease models to understand wound healing and fibrosis. RIDGEFIELD, CT, May 16, 2024 – XSeed Labs – a collaboration between BioMed X and Boehringer Ingelheim, announces the start of its first research team on the Boehringer Ingelheim camp in Ridgefield, Connecticut. This research team’s main objective is to develop complex, physiologically relevant disease models that deepen our understanding of dysfunctional wound healing and fibrosis. The end goal is to study fibrosis, drug delivery strategies, and drug safety in parallel, in an effort to bridge the gap between research and development to improve patient outcomes accurately and efficiently. The new research team is led by Dr. Lo…

-   Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders NORTH CHICAGO, Ill. and NEW YORK, May 13, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Gilgamesh Pharmaceuticals today announced a collaboration and option-to-license agreement to develop next-generation therapies for psychiatric disorders. This collaboration will leverage AbbVie's expertise in psychiatry and Gilgamesh's innovative research platform to discover novel neuroplastogens. Classic psychedelic compounds provide novel mechanisms to address mental health disorders, and some have shown promising clinical efficacy where other treatments have been ineffective. However, these first-generation comp…

The Danaher Beacon for Brain Injury Diagnostics seeks to identify mild Traumatic Brain Injury (TBI) earlier and more precisely. Scientists will evaluate new blood-based biomarkers using highly sensitive technology from Beckman Coulter Diagnostics. This approach could potentially be adapted for diagnosis of other neurological conditions. WASHINGTON, May 9, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a global science and technology innovator ("Danaher"), today launched a collaboration with Johns Hopkins University aiming to develop new methods for diagnosing mild TBI. As part of the Danaher Beacons program, researchers at Johns Hopkins University will leverage technology from Beckman Coulter Diagnostics, a Danaher subsidiary and leader in clinical diagnostics, to potentially est…

Flower Mound, Texas, USA – April 30, 2024 Stryker (NYSE: SYK), a global leader in medical technologies, announced today that it has completed the acquisition of mfPHD, a leader in modular stainless steel wall systems for hospitals and ambulatory surgery centers. Stryker will now be the provider of Fortress, a modular wall system that consolidates construction timelines, allowing for earlier operating room utilization as well as expedited room repair or modification when disruptive events occur. This acquisition allows for innovative product development opportunities to build out an ecosystem of embedded technologies delivering data and analytics for an intelligent operating room, minimizing downtime and costly renovations. "mfPHD aligns with Stryker’s enterprise strategic plans of expan…

New state-of-the-art research and development (R&D) facility at Ludwigshafen to expand discovery and development of new medicines across core therapeutic areas Investment reinforces the importance of the Rhineland-Palatinate site within AbbVie’s global network Construction of the new R&D building expected to complete in 2027 LUDWIGSHAFEN, Germany, April 29, 2024 – AbbVie breaks ground on a new central research building, “LUnA” (LUdwighafens neue Arbeitswelt) and is investing approximately €150 million in its second largest R&D location worldwide. A state-of-the-art research and laboratory building is being built on the main campus and will be home to more than 300 researchers and scientists. The facility will be built with modern and sustainable infrastructure features, creat…

MELBOURNE, Australia, April 17, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the Company has established a precision oncology division and announced its highly anticipated portfolio of new diagnostic tests under its geneType precision oncology brand. The proprietary-developed tests will provide invaluable information to medical oncologists, helping determine which therapies will have the most efficacious impact in treating a range of cancers including melanoma, lung, pancreatic, colorectal, breast, ovarian and brain cancers. Huge market opportunity for this advanced portfolio of methylation, mutation and liquid biopsy tests. Earlier d…

Lausanne, SWITZERLAND and San Francisco, CA, USA, 26 March 2024 - Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announces that it has joined the Critical Path Institute’s, Critical Path for Alzheimer’s Disease (CPAD) Consortium. With its highly experienced leadership team and world class Scientific Advisory Board of leading experts in neurodegenerative diseases, Asceneuron is well positioned to contribute to the consortium. Asceneuron has an exemplary pipeline of O-GlcNAcase (OGA) inhibitors in clinical development that have the potential to halt disease progression in neurodegenerative diseases. Its lead asset, ASN51, is a potential best-in-class, orally administered, OGA inhibitor targeting tau aggregation and…

Cambridge Cognition Holdings plc (AIM: COG) has established a Scientific Advisory Board to provide scientific counsel and market insights, focusing on integrating blood-based biomarkers, collaborative cognitive assessments, and diversity in clinical trials. Chaired by Liam Kaufman, the board includes Professor Judith Jaeger, Professor John Harrison, and Francesca Cormack. Professor Jaeger, a neuropsychologist with extensive experience in clinical trials, brings expertise in early-phase projects and regulatory meetings. Professor Harrison, known for his work in cognitive skills enhancement, has aided over 80 CNS drug development organizations and contributed to Alzheimer’s disease studies. Matthew Stork, CEO of Cambridge Cognition, highlights the board's role in aligning with evolving tre…

$250,000 top award goes to Achyuta Rajaram in the nation’s oldest and most prestigious Science, Technology, Engineering and Math (STEM) competition for high school seniors TARRYTOWN, N.Y. and WASHINGTON, D.C., March 12, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) announced that Achyuta Rajaram, 17, of Exeter, NH, won the top award in the Regeneron Science Talent Search (STS) 2024, America’s oldest and most prestigious science and math competition for high school seniors. The competition, now in its 83rd year, has consistently identified young innovators who become tomorrow’s STEM leaders. The 2024 finalists demonstrated extensive scientific knowledge through research and interviews while showcasing their commitment to addres…